Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2017Meditsinskiy sovet = Medical CouncilOpen Access

Sitagliptin protects against renal damage in T2DM with CKD via reduced inflammation in animal models.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does sitagliptin improve outcomes in Type 2 Diabetes Mellitus patients with chronic kidney disease?

Population

Type 2 Diabetes Mellitus patients with chronic kidney disease

Design

Review

Key result

Sitagliptin demonstrates a protective role against renal damage in type 2 diabetes mellitus with chronic kidney disease, with animal models showing regression of renal damage and reduced inflammation.

Authors

IBI. A. Bonda

Discussion

Loading...

Member takes

Overview

Should not yet change T2DM-CKD management; animal data leave open renoprotective effects for human trials.

Structured PICO

Does sitagliptin improve outcomes in Type 2 Diabetes Mellitus patients with chronic kidney disease?

P
Population
Type 2 Diabetes Mellitus patients with chronic kidney disease
I
Intervention
Sitagliptin

Sitagliptin is highlighted as a safe and effective treatment option for patients with type 2 diabetes and chronic kidney disease, with potential renoprotective effects.

Cite This Study

I. A. Bonda (2017) conducted a review in Type 2 Diabetes Mellitus with chronic kidney disease. Sitagliptin was evaluated. Sitagliptin demonstrates a protective role against renal damage in type 2 diabetes mellitus with chronic kidney disease, with animal models showing regression of renal damage and reduced inflammation.

synapsesocial.com/papers/6aa9581ea9624f76b4cdd839https://doi.org/10.21518/2079-701x-2017-11-170-175
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus2021 · 7 citations
  2. 2Sitagliptin: A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes2006 · 102 citations
  3. 3Sitagliptin is a time-tested leading drug in the treatment of type 2 diabetes2024
  4. 4Beyond Glycemic Control: Pleiotropic Effects of Sitagliptin2024
  5. 5Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease2018 · 6 citations